Astec LifeSciences Limited

For FY26 (year ended 31 Mar 2026), Astec LifeSciences Limited reported revenue of Rs 448 Cr and net profit of Rs -80.9 Cr, with a net margin of -18.05% and earnings per share of Rs -36.3 (consolidated statements).

Year-on-year change: revenue +17.13%; net profit not meaningful (a loss in one of the periods); EPS not meaningful (a loss in one of the periods). Three-year compound annual growth rate: revenue −10.92%; net profit not meaningful (a loss in one of the periods).

At the same date the balance sheet shows total assets of Rs 942 Cr, shareholders' equity of Rs 391 Cr, total debt of Rs 449 Cr, cash of Rs 10 Cr, a debt-to-equity ratio of 1.15 and operating cash flow of Rs -80.7 Cr.

On a trailing-twelve-month basis the filings add up to revenue of Rs 439 Cr, net income of Rs -79.5 Cr and a net margin of -18.12%.

In the shareholding pattern for 30 Sept 2026, Astec LifeSciences Limited's ownership is split: promoters 71.96%; foreign institutional investors (FIIs) 0.03%; domestic institutional investors (DIIs) 3.34%; retail and other shareholders 24.67%.

Compared with the filing for 30 Jun 2026: promoter holding 0.00 percentage points; FII holding +0.02 percentage points; DII holding +0.01 percentage points.

The same filing lists reported promoter pledge of 0.00% and 19,707 shareholders on record.

83 BSE corporate announcements were filed by Astec LifeSciences Limited in the past twelve months; the most frequent category is "Company Update" (56). The most recent is "Please find enclosed, newspaper publication of Financial Results for the Quarter and Half Year ended September 30, 2026." (Company Update), filed on 27 Oct 2026.

The disclosed corporate-action timeline lists 3 entries: dividend (2), rights (1). The latest is a rights (Right Issue of Equity Shares) with ex-date 4 Jul 2025.